We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01121198
Recruitment Status : Completed
First Posted : May 12, 2010
Last Update Posted : May 12, 2010
Information provided by:

Study Description
Brief Summary:
This study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ASP1941 in healthy adult male subjects.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Pharmacokinetics of ASP1941 Drug: ASP1941 Drug: placebo Phase 1

Detailed Description:
This study consists of two parts. In part-1, a single oral dose of ASP1941 or placebo is administered to healthy adult male subjects to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adult males. In part-2, ASP1941 or placebo are is administered by a multiple dose regimen.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Official Title: ASP1941 Phase I Study —Placebo-controlled, Single-dose and Repeated-dose Oral Administration Study in Healthy Adult Male Subjects—
Study Start Date : December 2006
Primary Completion Date : July 2007
Study Completion Date : July 2007
Arms and Interventions

Arm Intervention/treatment
Experimental: ASP1941 single arm Drug: ASP1941
Experimental: ASP1941 repeated arm Drug: ASP1941
Placebo Comparator: placebo single arm Drug: placebo
Placebo Comparator: placebo repeated arm Drug: placebo

Outcome Measures

Primary Outcome Measures :
  1. Safety assessed by adverse events, vital signs, 12-lead ECG and lab-tests [ Time Frame: 72 hours after drug administration ]

Secondary Outcome Measures :
  1. Plasma concentration of unchanged drug measured by blood sample [ Time Frame: 72 hours after drug administration ]
  2. Blood glucose level measured by blood sample [ Time Frame: 72 hours after drug administration ]
  3. Urinary glucose excretion level [ Time Frame: 72 hours after drug administration ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body weight: 50.0 kg ≤ weight < 85.0 kg
  • Body mass index:17.6 ≤ BMI < 26.4
  • Those who provided written informed consent themselves

Exclusion Criteria:

  • Medical history of Hepatic disease, heart disease, respiratory disease, gastrointestinal disease, renal disease, cerebrovascular disease, malignant tumor or drug allergy
  • Those whose blood pressure, pulse rate, body temperature or 12-lead ECG are in the abnormal range
  • Those whose lab-test results are in the abnormal range
  • Those who received medical treatment within 14 days prior to the study
  • Those who attended another clinical study or a post-marketing clinical trial within 120 days before the study
  • Those who have received ASP1941 before
  • Those who have donated at least 400ml of whole blood within 90 days before the study, at least 200ml 30 days before the study or blood component within 14 days before the study
  • Those within a fasting plasma glucose level of < 70mg/dL or 110 mg/dL or with an HbA1C. 5.8%
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01121198

Kantou, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Study Chair: Use Central Contact Astellas Pharma Inc
More Information

Responsible Party: Director, Astellas Pharma, Inc
ClinicalTrials.gov Identifier: NCT01121198     History of Changes
Other Study ID Numbers: 1941-CL-0101
First Posted: May 12, 2010    Key Record Dates
Last Update Posted: May 12, 2010
Last Verified: May 2010

Keywords provided by Astellas Pharma Inc:
Food effect